CRISPR Therapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating
CRISPR Therapeutics has crossed a key technical hurdle by surpassing an 80 Relative Strength Rating. The biotech company’s performance signals notable momentum in a competitive market space.
2 days ago
2 mins read